A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukemia
Cancer · 2025
DOI: 10.1002/cncr.35813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Alexandre Bazinet und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Mutation, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: The University of Texas MD Anderson Cancer Center Support Grant, The University of Texas MD Anderson Cancer Center Myelodysplastic Syndrome/Acute Myeloid Leukemia Moon Shot.
Abstract (Originalsprache)
Background
FMS‐like tyrosine kinase 3 ( FLT3 ) mutations, either internal tandem duplications ( FLT3 ‐ITD) or tyrosine kinase domain ( FLT3 ‐TKD), are common in acute myeloid leukemia (AML). FLT3 ‐ITD confers an adverse prognosis.
Methods
The authors performed a retrospective study including 619 patients to evaluate outcomes in newly diagnosed FLT3 ‐mutated AML across treatment regimens.
Results
In patients with FLT3 ‐ITD–mutated AML who received intensive chemotherapy (IC), the addition of a FLT3 inhibitor (FLT3i) was associated with trends toward improved relapse‐free survival (median 32.3 vs. 14.3 months with vs. without a FLT3i; p = .055) and overall survival (OS; 35.5 vs. 18.9 months with vs. without a FLT3i; p = .098). In patients with FLT3 ‐ITD mutations who received low‐intensity (LIT) regimens, triplets (LIT plus a FLT3i plus venetoclax) were associated with significantly longer OS (19.1 months) compared with those who received other treatment combinations (11.2 months with LIT alone, 9.2 months with LIT plus FLT3i, and 10.3 months with LIT plus venetoclax). Patients with FLT3 ‐ITD plus NPM1 co‐mutations who received any therapy had a trend toward improved OS (2‐year OS: 47% vs. 33%; p = .087). The FLT3 ‐ITD allelic ratio; IDH1 , IDH2 , WT1 , RUNX1 , and myelodysplastic syndrome‐related mutations; and adverse cytogenetics had no significant impact on OS. In landmark analyses, allogeneic stem cell transplantation was associated with a trend toward improved OS in patients with FLT3 ‐ITD mutations who received IC (52.6 vs. 22.7 months with versus without allogeneic stem cell transplantation; p = .076) and a marked improvement in OS in those who received LIT (38.6 vs. 14.0 months with vs. without allogeneic stem cell transplantation; p < .0001).
Conclusions
A FLT3i and allogeneic stem cell transplantation are key treatment modalities for patients who have FLT3 ‐mutated AML. LIT‐based triplets are promising in IC‐ineligible patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Alexandre Bazinet, Alex Bataller, Tapan Kadia, Naval Daver, Nicholas J Short, Koji Sasaki, Courtney D DiNardo, Ian Bouligny, Guillermo Garcia-Manero, Hagop M Kantarjian
Förderung
- The University of Texas MD Anderson Cancer Center Support Grant
- The University of Texas MD Anderson Cancer Center Myelodysplastic Syndrome/Acute Myeloid Leukemia Moon Shot
Zitieren
APA
Bazinet, A., Bataller, A., Kadia, T., Daver, N., Short, N. J., Yilmaz, M., Sasaki, K., DiNardo, C. D., Borthakur, G. M., Issa, G., Bouligny, I., Pierce, S., Garcia-Manero, G., Ravandi, F., & Kantarjian, H. M. (2025). A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukemia. Cancer. https://doi.org/10.1002/cncr.35813
Vancouver
Bazinet A, Bataller A, Kadia T, Daver N, Short NJ, Yilmaz M, et al. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukemia. Cancer. 2025. doi:10.1002/cncr.35813
BibTeX
@article{Bazinet2025,
author = {Bazinet, Alexandre and Bataller, Alex and Kadia, Tapan and Daver, Naval and Short, Nicholas J and Yilmaz, Musa and Sasaki, Koji and DiNardo, Courtney D and Borthakur, Gautam M and Issa, Ghayas and Bouligny, Ian and Pierce, Sherry and Garcia-Manero, Guillermo and Ravandi, Farhad and Kantarjian, Hagop M},
title = {A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukemia},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35813}
}
EUVIMED